Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0KAFYS
ADC Name	TROP2-IR700
Synonyms	TROP2-IR700 conjugate Click to Show/Hide
Drug Status	Investigative
Indication	In total 2 Indication(s) Cholangiocarcinoma [ICD11:2C12] Investigative Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	3
	3D MOL	2D MOL
Antibody Name	Anti-TROP2 mAb T6-16		Antibody Info
Antigen Name	Tumor-associated calcium signal transducer 2 (TACSTD2)		Antigen Info
Payload Name	IRDye 700DX		Payload Info
Linker Name	Undisclosed

General Information of The Activity Data Related to This ADC

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	≈ 49.5	%	PK-59 cells	Pancreatic carcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 49.50% (Day 14)	Positive TROP2 expression (TROP2+++/++)
Method Description	Five million of PK59 or TFK1 cells were injected subcutaneously into the right dorsum of the mice. Five million of 3T3/HER2 cells were injected subcutaneously into the left dorsum of the mice as negative control. The dose of ADC was 200 ug TROP2-IR700.
In Vivo Model	PK59 CDX model
In Vitro Model	Pancreatic carcinoma	PK-59 cells		CVCL_4897

References

Ref 1	Photoimmunotherapy targeting biliary-pancreatic cancer with humanized anti-TROP2 antibody. Cancer Med. 2019 Dec;8(18):7781-7792. doi: 10.1002/cam4.2658. Epub 2019 Nov 1.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.